Davami, Fatemeh

[ 1 ] - A Comparative Investigation of the Bispecific Antibody: Expression in Expi293F Cells and E.Coli

Aims: Bispecific antibodies are capable of targeting two cell surface markers simultaneously. Blinatumomab an anti-CD3/CD19 Bispecific T cell engager antibody (BiTE) is approved for clinical application by FDA. This BiTE effectively targets malignant cells in ALL (Acute Lymphoblastic Leukemia) patients. For production of large quantities of such antibodies in industrial settings choice of host ...